The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trial
Open accessAbstract
BACKGROUND This two-stage randomised controlled trial, comparing total laparoscopic hysterectomy (TLH) with total abdominal hysterectomy (TAH) for stage I endometrial cancer (LACE), began in 2005. The primary objective of stage 1 was to assess whether TLH results in equivalent or improved quality of life (QoL) up to 6 months after surgery compared with TAH. The primary objective of stage 2 was to test the hypothesis that disease-free survival at 4.5 years is equivalent for TLH and TAH. Here, we present the results of stage 1. METHODS Between Oct 7, 2005, and April 16, 2008, 361 participants were enrolled in the QoL substudy at 19 centres across Australia, New Zealand, and Hong Kong; 332 completed the QoL analysis. Randomisation was done centrally and independently from other study procedures via a computer-generated, web-based system (providing concealment of the next assigned treatment), using stratified permuted blocks of three and six patients. Patients with histologically confirmed stage I endometrioid adenocarcinoma and Eastern Cooperative Oncology Group performance status less than 2 were randomly assigned to TLH (n=190) or TAH (n=142), stratified by histological grade and study centre. Patients and study personnel were not masked to treatment assignment. QoL was measured at baseline, 1 and 4 weeks (early), and 3 and 6 months (late) after surgery, using the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire. The primary endpoint was the difference between groups in QoL change from baseline at early and late timepoints (a 5% difference was considered clinically significant). Analysis was done according to the intention-to-treat principle. Patients for both stages of the trial have now been recruited and are being followed up for disease-specific outcomes. The LACE trial is registered with ClinicalTrials.gov, number NCT00096408. FINDINGS Eight of 332 patients (2.4%) had treatment conversion-seven from TLH to TAH and one from TAH to TLH (patient preference). In the early phase of recovery, patients who had TLH reported significantly greater improvement in QoL from baseline compared with those who had TAH, in all subscales apart from emotional and social wellbeing. Improvements in QoL up to 6 months after surgery continued to favour TLH, except in the emotional and social wellbeing measures of FACT and the visual analogue scale of the EuroQoL five dimensions (EuroQoL-VAS). Operating time was significantly longer in the TLH group (138 min [SD 43]) than in the TAH group (109 min [34]; p=0.001). Although the proportion of intraoperative adverse events was similar between groups (TAH eight of 142 [5.6%] vs TLH 14 of 190 [7.4%]; p=0.53); postoperatively, twice as many patients in the TAH group experienced adverse events of grade 3 or higher (33 of 142 [23.2%] vs 22 of 190 [11.6%] in the TLH group; p=0.004). Postoperative serious adverse events occurred more in the TAH group (27 of 142 [19.0%]) than in the TLH group (16 of 190 [7.9%]; p=0.002). INTERPRETATION QoL improvements from baseline during early and later phases of recovery, and the adverse event profile, favour TLH compared with TAH for treatment of stage I endometrial cancer. FUNDING Cancer Council Queensland, Cancer Council New South Wales, Cancer Council Victoria, Cancer Council Western Australia; NHMRC project grant 456110; Cancer Australia project grant 631523; The Women and Infants Research Foundation, Western Australia; Royal Brisbane and Women's Hospital Foundation; Wesley Research Institute; Gallipoli Research Foundation; Gynetech; TYCO Healthcare, Australia; Johnson and Johnson Medical, Australia; Hunter New England Centre for Gynaecological Cancer; Genesis Oncology Trust; and Smart Health Research Grant QLD Health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020 · cited 1×
“The primary outcome measure of QoL was the Functional Assessment of Cancer TherapyGeneral (FACT-G) Version 4 questionnaire (21).”
BackgroundRevised FIGO staging for carcinoma of the vulva, cervix, and endometrium
Pecorelli, S. (2009) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2009.02.012 · Cited by 2,881
Walker, J. L., Piedmonte, M. R., Spirtos, N. M., Eisenkop, S. M., Schlaerth, J. B., Mannel, R. S., Spiegel, G., Barakat, R., Pearl, M. L., & Sharma, S. K. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3248 · Cited by 1,288
A body image scale for use with cancer patients
Hopwood, P., Fletcher, I., Lee, A., & Al Ghazal, S. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00353-1 · Cited by 984
CREASMAN, W., ODICINO, F., MAISONNEUVE, P., QUINN, M., BELLER, U., BENEDET, J., HEINTZ, A., NGAN, H., & PECORELLI, S. (2006) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(06)60031-3 · Cited by 966
Self-citationChallenges in evaluating surgical innovation
Ergina, P. L., Cook, J. A., Blazeby, J. M., Boutron, I., Clavien, P.-A., Reeves, B. C., & Seiler, C. M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61086-2 · Cited by 653
Creasman, W. T., Odicino, F., Maisonneuve, P., Beller, U., Benedet, J. L., Heintz, A. P. M., Ngan, H. Y. S., & Pecorelli, S. (2003) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(03)90116-0 · Cited by 579
Self-citationYost, K. J., & Eton, D. T. (2005) · Evaluation & the Health Professions · doi:10.1177/0163278705275340 · Cited by 382
Practical gynecologic oncology
Berek, J. S., & Hacker, N. F. (1989) · Cited by 364
Cited by
Morice, P., Leary, A., Creutzberg, C., Abu-Rustum, N., & Darai, E. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00130-0 · Cited by 1,514
Walker, J. L., Piedmonte, M. R., Spirtos, N. M., Eisenkop, S. M., Schlaerth, J. B., Mannel, R. S., Barakat, R., Pearl, M. L., & Sharma, S. K. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8645 · Cited by 784
Makker, V., MacKay, H., Ray-Coquard, I., Levine, D. A., Westin, S. N., Aoki, D., & Oaknin, A. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00324-8 · Cited by 674
Lu, K. H., & Broaddus, R. R. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1514010 · Cited by 663
Janda, M., Gebski, V., Davies, L. C., Forder, P., Brand, A., Hogg, R., Jobling, T. W., Land, R., Manolitsas, T., Nascimento, M., et al. (2017) · JAMA · doi:10.1001/jama.2017.2068 · Cited by 447
Self-citation
Metadata
- Authors
- Janda, M., Gebski, V., Brand, A., Hogg, R., Jobling, T. W., Land, R., Manolitsas, T., McCartney, A., Nascimento, M., Neesham, D., Nicklin, J. L., Oehler, M. K., Otton, G., Perrin, L., Salfinger, S., Hammond, I., Leung, Y., Walsh, T., Sykes, P., Ngan, H., Garrett, A., Laney, M., Ng, T. Y., Tam, K., Chan, K., Wrede, C. D. H., Pather, S., Simcock, B., Farrell, R., & Obermair, A.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2010-08
- Volume
- 11
- Issue
- 8
- Pages
- 772-780
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2117286559
- Cited by
- 358
- References
- 25
- FWCI
- 33.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trial. https://app.cochat.ai/papers/10.1016/s1470-2045(10)70145-5
- The paper
- Janda, M., Gebski, V., Brand, A., Hogg, R., Jobling, T. W., Land, R., Manolitsas, T., McCartney, A., Nascimento, M., Neesham, D., Nicklin, J. L., Oehler, M. K., Otton, G., Perrin, L., Salfinger, S., Hammond, I., Leung, Y., Walsh, T., Sykes, P., . . . Obermair, A. (2010). Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(10)70145-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.